-
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Friday, June 28, 2024 - 11:03am | 1549Read More...Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...
-
Danaher's Cepheid Receives FDA Emergency Use Authorization For 45-Minute Coronavirus Test
Sunday, March 22, 2020 - 8:20am | 347Read More...Late Friday night, the U.S. Food And Drug Administration approved the first coronavirus test that can be conducted entirely at the point of care for a patient and deliver results in 45 minutes. Cepheid's Xpert Xpress SARS-CoV-2 is a rapid molecular diagnostic test for qualitative detection of...
-
Analogic Earnings Preview: EPS Expected to Double
Wednesday, December 7, 2011 - 7:46am | 648Read More...Analogic (NASDAQ: ALOG) is scheduled to report fiscal first-quarter 2012 results tomorrow, December 8, after the closing bell. The Massachusetts-based tech company is in transition, having last week announced the most comprehensive transformation of its corporate brand in its more than 40 year...
-
Piper Jaffray Raises PT On Cepheid To $38
Thursday, June 23, 2011 - 6:06am | 26Read More...Piper Jaffray has raised the price target on Cepheid (NASDAQ: CPHD) from $33 to $38 and maintains its Overweight rating.
-
UPDATE: Jefferies Raises PT on Cepheid to $35 (CPHD)
Thursday, April 21, 2011 - 8:33am | 82Read More...Jefferies is out with its report today on Cepheid (NASDAQ: CPHD), raising its PT from $30 to $35. In a note to clients, Jefferies writes, "CPHD's 1Q11 GAAP EPS of $0.01 was $0.02 ahead of consensus on better than expected revenue growth and profit trends. We are raising our 2011 and 2012 EPS...
-
UPDATE: Piper Jaffray Raises PT on Cepheid to $33 (CPHD)
Thursday, April 21, 2011 - 7:52am | 125Read More...Piper Jaffray is out with its report today on Cepheid (NASDAQ: CPHD), raising its PT from $29 to $33. In a note to clients, Piper Jaffray writes, "Cepheid reported 1Q11 results above our and Street consensus expectations, with both revenue and EPS ahead of our estimates. Instrument revenue ($12.7M...
-
Jefferies Raises PT On Cepheid To $35
Thursday, April 21, 2011 - 7:04am | 26Read More...Jefferies & Company has raised the price target on Cepheid (NASDAQ: CPHD) from $30 to $35 and maintains its Buy rating.
-
Piper Jaffray Raises PT On Cepheid To $33
Thursday, April 21, 2011 - 6:41am | 26Read More...Piper Jaffray has raised the price target on Cepheid (NASDAQ: CPHD) from $29 to $33 and maintains its Overweight rating.
-
Goldman Sachs Raises CPHD Target From $30 To $32
Thursday, April 14, 2011 - 7:40am | 26Read More...Goldman Sachs is raising its PT on shares of Cepheid (NASDAQ: CPHD) from $30 to $32. Cepheid closed Wednesday at $28.75.
-
Wedbush Reaffirms Neutral Rating On CPHD
Tuesday, April 12, 2011 - 9:18am | 153Read More...Wedbush is reaffirming its Neutral rating on Cepheid (NASDAQ: CPHD). “Shares of CPHD are up 25% over the last three months versus 5% appreciation in the S&P 500 over the same period,” Wedbush writes. “While we are not hearing anything negative from the channel, we remain NEUTRAL until we...
-
Oppenheimer Initiates CPHD At Outperform, $33 PT
Wednesday, March 16, 2011 - 4:52pm | 80Read More...Oppenheimer is initiating coverage of Cepheid (NASDAQ: CPHD) with an Outperform rating and $33 target price. “Cepheid is a pure play molecular diagnostic company with a pioneering technology platform, the GeneXpert,” Oppenheimer writes. “Expansion of the testing menu with the launch of CT/NG and...
-
Piper Jaffray Raises PT On Cepheid To $29
Friday, January 28, 2011 - 9:20am | 26Read More...Piper Jaffray has raised the price target on Cepheid (NASDAQ: CPHD) from $22 to $29 and maintains its Overweight rating.
